Iting–review and editing, B.Y.C., A.R.K. and S.W.S.; visualization, S.H.L. (Song Hee Lee); supervision, H.C.C., H.K.S. and S.W.S.; project administration, S.W.S.; funding acquisition, S.W.S. All authors have read and agreed for the published version with the manuscript.Nutrients 2022, 14,15 ofFunding: This study was supported by funding from the National Research Foundation of Korea (NRF) (NRF-2021R1A6A3A01087054 to S.H.L. (Song Hee Lee); NRF-2020R1A2C2008480 to S.W.S.) and by the Korea Wellness Technology R D Project via the Korea Overall health Business Development Institute (KHIDI) funded by the Ministry of Wellness Welfare, Republic of Korea (grant quantity: HI20C0408), awarded to C.H.P. In addition, this analysis was supported by the Korea Well being Technology R D Project through the Korea Well being Business Development Institute (KHIDI) and the Korea Dementia Study Center (KDRC), funded by the Ministry of Health Welfare and Ministry of Science and ICT, Republic of Korea (grant number: HU20C0206), awarded to S.W.S. Institutional Assessment Board Statement: This study was approved and carried out in accordance with all the Laboratory Animal Guide published by the National Institute of Well being (NIH), Chuncheon Hallym University Laboratory Animal Research Management and Utilization Committee Rules (Protocol Hallym R1 (2018-17), approval date 17 April 2018). Informed Consent Statement: Not applicable. Information Availability Statement: Not applicable. Conflicts of Interest: The authors declare no conflict of interest.
Coronavirus disease-2019 (COVID-19), caused by extreme acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), broke out in late 2019 to become a significant global threat to human wellness. Within the absence of certain treatments for COVID-19, therapy options are becoming examined. Lately, the anti-SARS-CoV-2 activities of tetracyclines [e.g., doxycycline (DOX)], macrolide antibiotics [e.g., azithromycin (AZM), and clarithromycin(CAM)], and macrolide antiparasitic [e.g., ivermectin (IVM)], have attracted considerable interest for their potential as a single or multi-drug treatment regimen.Cyclophilin A, Mouse (tag free) Apart from anti-SARS-CoV-2 activities, DOX, AZM, and IVM possess anti-inflammatory and immunomodulatory effects to lower the production of interleukin-6 (IL-6), IL-8, and tumor necrosis factor- (TNF-); IL-1, IL-6, IL-8, and TNF-; and IL-1, IL-6, and TNF-, respectively.RNase Inhibitor Publications 1-Correspondence: oektsp1218@sweet.PMID:23376608, Telephone: +07069574159, ORCID-ID: Received: 19.07.2021, Accepted: 06.09.�Turk J Pharm Sci, Published by Galenos Publishing Residence.Masashi OHE. Multi-drug Therapy for COVID-In single-drug treatment studies in COVID-19, DOX,4 CAM,5 and IVM6 have proven successful against COVID-19. In multi-drug treatment research, Alam et al.7 identified that a combination of IVM and DOX was helpful for viral clearance in patients with mild and moderate COVID-19. Prasad8 reported on a patient exactly where COVID-19 accompanied by pulmonary lesion was effectively treated with all the early administration of IVM (6 mg twice daily for three days), AZM (500 mg day-to-day for 5 days), DOX (100 mg twice every day for 5 days), and prednisolone (50 mg daily for 5 days) followed by dexamethasone (6 mg each day). The main objective of your aforementioned drug treatment options would be to strengthen mild and moderate COVID-19 cases and avert them from additional deteriorating into the serious, life-threatening stage. Extreme COVID-19 entails cytokine storm-associated organ damage, which includes acute respirator.